Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis

Cancer Biology and Therapy

Volumn 15, Issue 11, 2014, Pages 1479-1488

  Dong, Fengyun ^a   Zhou, Xia ^a   Li, Changsheng ^a   Yan, Suhua ^a   Deng, Xianming ^b   Cao, Zhiqun ^c   Li, Liqun ^a   Tang, Bo ^d   Allen, Thaddeus D ^e   Liu, Ju ^a  

^a SHANDONG UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c Shandong Institute of Traditional Chinese Medicine   (China)

^d SHANDONG NORMAL UNIVERSITY   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Dihydroartemisinin; Endothelial cells; NF B; VEGFR2

Indexed keywords

DIHYDROARTEMISININ; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PYRROLIDINE DITHIOCARBAMATE; SYNAPTOTAGMIN I; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; ARTEMISININ DERIVATIVE; PROLINE; PROLINEDITHIOCARBAMATE; PROTEIN BINDING; THIOCARBAMIC ACID DERIVATIVE; TRANSCRIPTION FACTOR RELA;

ANGIOGENESIS ASSAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; ANALOGS AND DERIVATIVES; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL MOTION; DRUG EFFECTS; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE MOTIF; RETINA; RETINA BLOOD VESSEL; TRANSCRIPTION INITIATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ARTEMISININS; BINDING SITES; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; NUCLEOTIDE MOTIFS; PROLINE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RETINA; RETINAL VESSELS; SIGNAL TRANSDUCTION; THIOCARBAMATES; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84918546040     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.955728     Document Type: Article

References (50)

1. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-4; PMID:9109485; http://dx.doi.org/10.1038/386671a0
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31; PMID:7584949; http://dx.doi.org/10.1038/nm0195-27
3. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-6; PMID:16355210; http://dx.doi.org/10.1038/nature04478.
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-74; PMID:16355214; http://dx.doi.org/10.1038/nature04483.
5. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005; 438:937-45; PMID:16355211; http://dx.doi.org/10.1038/nature04479.
6. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12:303-24; PMID:8281615; http://dx.doi.org/10.1007/BF00665960.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-76; PMID:12778165; http://dx.doi.org/10.1038/nm0603669.
8. Kolch W, Martiny-Baron G, Kieser A, Marme D. Regulation of the expression of the VEGFVPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat 1995; 36:139-55; PMID:8534863; http://dx.doi.org/10.1007/BF00666036.
9. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307; PMID:21593862; http://dx.doi.org/10.1038/nature10144.
10. Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, Shibuya M. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann N Y Acad Sci 2000; 902:201-5; discussion 5-7; PMID:10865839; http://dx.doi.org/10.1111/j.1749-6632.2000.tb06314.x.
11. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228:1049-55; PMID:3887571; http://dx.doi.org/10.1126/science.3887571.
12. Gordi T, Lepist EI. Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett 2004; 147:99-107; PMID:14757313; http://dx.doi.org/10.1016/j.toxlet.2003.12.009.
13. Tu Y. The development of new antimalarial drugs: qinghaosu and dihydro-qinghaosu. Chin Med J (Engl) 1999; 112:976-7; PMID:11721477.
14. Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012; 2012:247597; PMID:22174561; http://dx.doi.org/10.1155/2012/247597.
15. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001; 18:767-73; PMID:11251172.
16. Dell'Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, Efferth T. Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol 2004; 68:2359-66; http://dx.doi.org/10.1016/j.bcp.2004.08.021.
17. Zhang CZ, Zhang H, Yun J, Chen GG, Lai PB. Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 2012; 83:1278-89; PMID:22342732; http://dx.doi.org/10.1016/j.bcp.2012.02.002.
18. Zhou HJ, Zhang JL, Li A, Wang Z, Lou XE. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother Pharmacol 2010; 66:21-9; PMID:19756601; http://dx.doi.org/10.1007/s00280-009-1129-z.
19. Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010; 80:22-30; PMID:20206143; http://dx.doi.org/10.1016/j.bcp.2010.02.016.
20. Longo M, Zanoncelli S, Torre PD, Riflettuto M, Cocco F, Pesenti M, Giusti A, Colombo P, Brughera M, Mazue G, et al. In vivo and in vitro investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) on rat embryos. Reprod Toxicol 2006; 22:797-810; PMID:16959470; http://dx.doi.org/10.1016/j.reprotox.2006.08.001.
21. Chen HH, Zhou HJ, Wang WQ, Wu GD. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 2004; 53:423-32; PMID:15132130; http://dx.doi.org/10.1007/s00280-003-0751-4.
22. Chen HH, Zhou HJ, Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 2003; 48:231-6; PMID:12860439; http://dx.doi.org/10.1016/S1043-6618(03)00107-5.
23. Wu GD, Zhou HJ, Wu XH. Apoptosis of human umbilical vein endothelial cells induced by artesunate. Vascular Pharmacol 2004; 41:205-12; PMID:15653096; http://dx.doi.org/10.1016/j.vph.2004.11.001.
24. D'Alessandro S, Basilico N, Corbett Y, Scaccabarozzi D, Omodeo-Sale F, Saresella M, Marventano I, Vaillant M, Olliaro P, Taramelli D. Hypoxia modulates the effect of dihydroartemisinin on endothelial cells. Biochem Pharmacol 2011; 82:476-84; http://dx.doi.org/10.1016/j.bcp.2011.06.002.
25. Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascular Pharmacol 2007; 47:131-8; PMID:17581794; http://dx.doi.org/10.1016/j.vph.2007.05.002.
26. Wang SJ, Sun B, Cheng ZX, Zhou HX, Gao Y, Kong R, Chen H, Jiang HC, Pan SH, Xue DB, et al. Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-kappaB pathway. Cancer Chemother Pharmacol 2011; 68:1421-30; PMID:21479633; http://dx.doi.org/10.1007/s00280-011-1643-7.
27. Terman BI, Dougher-Vermazen M. Biological properties of VEGFVPF receptors. Cancer Metastasis Rev 1996; 15:159-63; PMID:8842487; http://dx.doi.org/10.1007/BF00437468.
28. Ronicke V, Risau W, Breier G. Characterization of the endothelium-specific murine vascular endothelial growth factor receptor-2 (Flk-1) promoter. Circ Res 1996; 79:277-85; PMID:8756005; http://dx.doi.org/10.1161/01.RES.79.2.277.
29. Huxford T, Huang DB, Malek S, Ghosh G. The crystal structure of the IkappaBalphaNF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 1998; 95:759-70; PMID:9865694; http://dx.doi.org/10.1016/S0092-8674(00)81699-2.
30. Jacobs MD, Harrison SC. Structure of an IkappaBal-phaNF-kappaB complex. Cell 1998; 95:749-58; PMID:9865693; http://dx.doi.org/10.1016/S0092-8674(00)81698-0.
31. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 2007; 26:7324-32; PMID:17533369; http://dx.doi.org/10.1038/sj.onc.1210544.
32. Haussler U, von Wichert G, Schmid RM, Keller F, Schneider G. Epidermal growth factor activates nuclear factor-kappaB in human proximal tubule cells. Am J Physiol Renal Physiol 2005; 289:F808-15; PMID:15798085; http://dx.doi.org/10.1152/ajprenal.00434.2003.
33. Patterson C, Perrella MA, Hsieh CM, Yoshizumi M, Lee ME, Haber E. Cloning and functional analysis of the promoter for KDRflk-1, a receptor for vascular endothelial growth factor. J Biol Chem 1995; 270:23111-8; PMID:7559454; http://dx.doi.org/10.1074/jbc.270.39.23111.
34. Minami T, Rosenberg RD, Aird WC. Transforming growth factor-beta 1-mediated inhibition of the flk-1KDR gene is mediated by a 5′-untranslated region palindromic GATA site. J Biol Chem 2001; 276:5395-402; PMID:11098056; http://dx.doi.org/10.1074/jbc.M008798200.
35. Ziegler-Heitbrock HW, Sternsdorf T, Liese J, Belohradsky B, Weber C, Wedel A, Schreck R, Bauerle P, Strobel M. Pyrrolidine dithiocarbamate inhibits NF-kappa B mobilization and TNF production in human monocytes. J Immunol 1993; 151:6986-93; PMID:8258705.
36. Liu SF, Ye X, Malik AB. Pyrrolidine dithiocarbamate prevents I-kappaB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol 1999; 55:658-67; PMID:10101023.
37. Yoshida A, Yoshida S, Ishibashi T, Kuwano M, Inomata H. Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice. Invest Ophthalmol Vis Sci 1999; 40:1624-9; PMID:10359349.
38. Ho WE, Peh HY, Chan TK, Wong WS. Artemisinins: Pharmacological actions beyond anti-malarial. Pharmacol Ther 2013; PMID:24316259.
39. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12:895-904; PMID:16892035; http://dx.doi.org/10.1038/nm1469.
40. Yamaguchi TP, Dumont DJ, Conlon RA, Breitman ML, Rossant J. flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development 1993; 118:489-98; PMID:8223275.
41. DeBusk LM, Massion PP, Lin PC. IkappaB kinase-alpha regulates endothelial cell motility and tumor angiogenesis. Cancer Res 2008; 68:10223-8; PMID:19074890; http://dx.doi.org/10.1158/0008-5472.CAN-08-1833.
42. Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, Shibata W, Yanai A, Ogura K, Omata M. Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res: An Off J Am AssocCancer Res 2009; 15:2248-58; PMID:19276252; http://dx.doi.org/10.1158/1078-0432.CCR-08-1383.
43. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS, Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276:22382-7; PMID:11297551; http://dx.doi.org/10.1074/jbc.M100938200.
44. Calzado MA, Bacher S, Schmitz ML. NF-kappaB inhibitors for the treatment of inflammatory diseases and cancer. Curr Med Chem 2007; 14:367-76; PMID:17305539; http://dx.doi.org/10.2174/092986707779941113.
45. Brouard S, Berberat PO, Tobiasch E, Seldon MP, Bach FH, Soares MP. Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis. J Biol Chem 2002; 277:17950-61; PMID:11880364; http://dx.doi.org/10.1074/jbc.M108317200.
46. Martin D, Galisteo R, Gutkind JS. CXCL8IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3Bcl10Malt1) complex. J Biol Chem 2009; 284:6038-42; PMID:19112107; http://dx.doi.org/10.1074/jbc.C800207200.
47. Wang J, Guo Y, Zhang BC, Chen ZT, Gao JF. Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. Pharmacology 2007; 80:207-18; PMID:17622766; http://dx.doi.org/10.1159/000104418.
48. Zhong YY, Zhang HF, Zhong JX, Bai L, Lu XH. Topical dihydroartemisinin inhibits suture-induced neovascularization in rat corneas through ERK12 and p38 pathways. Int J Ophthalmol 2011; 4:150-5; PMID:22553631.
49. Gariano RF. Special features of human retinal angiogenesis. Eye (Lond) 2010; 24:401-7; PMID:20075971; http://dx.doi.org/10.1038/eye.2009.324.
50. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 2010; 29:500-19; PMID:20488255; http://dx.doi.org/10.1016/j.preteyeres.2010.05.003.